

## Brilliant Violet 421™ anti-mouse CD45 Antibody

<b>Catalog# / Size</b>	103133 / 125 µL 103134 / 50 µg
<b>Clone</b>	30-F11
<b>Regulatory Status</b>	RUO
<b>Other Names</b>	T200, Ly-5, LCA
<b>Isotype</b>	Rat IgG2b, κ
<b>Description</b>	CD45 is a 180-240 kD glycoprotein also known as the leukocyte common antigen (LCA), T200, or Ly-5. It is a member of the protein tyrosine phosphatase (PTP) family, expressed on all hematopoietic cells except mature erythrocytes and platelets. There are different isoforms of CD45 that arise from variable splicing of exons 4, 5, and 6, which encode A, B, and C determinants, respectively. CD45 plays a key role in TCR and BCR signal transduction. These isoforms are very specific to the activation and maturation state of the cell as well as cell type. The primary ligands for CD45 are galectin-1, CD2, CD3, CD4, TCR, CD22, and Thy-1.

### Product Details

---

<b>Verified Reactivity</b>	Mouse
<b>Antibody Type</b>	Monoclonal
<b>Host Species</b>	Rat
<b>Immunogen</b>	Mouse thymus or spleen
<b>Formulation</b>	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
<b>Preparation</b>	The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421™ under optimal conditions.
<b>Concentration</b>	µg sizes: 0.2 mg/mL µL sizes: lot-specific (to obtain lot-specific concentration, please enter the lot number in our <a href="#">Concentration and Expiration Lookup</a> or <a href="#">Certificate of Analysis</a> online tools.)
<b>Storage &amp; Handling</b>	The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. <b>Do not freeze.</b>
<b>Application</b>	<a href="#">FC - Quality tested</a> <a href="#">SB - Reported in the literature. not verified in house</a>
<b>Recommended Usage</b>	<p>Each lot of this antibody is quality control tested by <a href="#">immunofluorescent staining with flow cytometric analysis</a>. For immunofluorescent staining using the µg size, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. For immunofluorescent staining using the µl size, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.</p> <p>Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd.</p> <p><a href="#">Learn more about Brilliant Violet™.</a></p> <p>This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.</p>
<b>Excitation Laser</b>	Violet Laser (405 nm)
<b>Application Notes</b>	Clone 30-F11 reacts with all isoforms and both CD45.1 and CD45.2 alloantigens of CD45.

Additional reported applications (for relevant formats) include: immunoprecipitation<sup>3</sup>, complement-dependent cytotoxicity<sup>1,5</sup>, immunohistochemistry (acetone-fixed frozen sections, zinc-fixed paraffin-embedded sections and formalin-fixed paraffin-embedded sections)<sup>4,6</sup>, Western blotting<sup>7</sup>, and spatial biology (IBEX)<sup>10,11</sup>. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/μg, Azide-Free, 0.2 μm filtered) is recommended for functional assays (Cat. No. 103163 and 103164).

#### Additional Product Notes

Iterative Bleaching Extended multi-plexity (IBEX) is a fluorescent imaging technique capable of highly-multiplexed spatial analysis. The method relies on cyclical bleaching of panels of fluorescent antibodies in order to image and analyze many markers over multiple cycles of staining, imaging, and, bleaching. It is a community-developed open-access method developed by the Center for Advanced Tissue Imaging (CAT-I) in the National Institute of Allergy and Infectious Diseases (NIAID, NIH).

#### Application References

(PubMed link indicates BioLegend citation)

1. Podd BS, *et al.* 2006. *J. Immunol.* 176:6532. (FC, CMCD) [PubMed](#)
2. Haynes NM, *et al.* 2007. *J. Immunol.* 179:5099. (FC)
3. Ledbetter JA, *et al.* 1979. *Immunol. Rev.* 47:63. (IP)
4. Simon DI, *et al.* 2000. *J. Clin. Invest.* 105:293. (IHC)
5. Seaman WE. 1983. *J. Immunol.* 130:1713. (CMCD)
6. Cornet A, *et al.* 2001. *P. Natl. Acad. Sci. USA* 98:13306. (IHC)
7. Tsuboi S and Fukuda M. 1998. *J. Biol. Chem.* 273:30680. (WB) [PubMed](#)
8. Liu F, *et al.* 2012. *Blood.* 119:3295. [PubMed](#)
9. Pelletier AN, *et al.* 2012. *J. Immunol.* 188:5561. [PubMed](#)
10. Radtke AJ, *et al.* 2020. *Proc Natl Acad Sci U S A.* 117:33455-65. (SB) [PubMed](#)
11. Radtke AJ, *et al.* 2022. *Nat Protoc.* 17:378-401. (SB) [PubMed](#)

#### Product Citations

1. Zahr A, *et al.* 2016. *Nat Commun.* 7:10363. [PubMed](#)
2. Naito H, *et al.* 2020. *Nature Protocols.* 15(3):1066-1081. [PubMed](#)
3. Schlecht A, *et al.* 2021. *Int J Mol Sci.* 22: . [PubMed](#)
4. Cullis J, *et al.* 2017. *Cancer Immunol Res.* 5:182. [PubMed](#)
5. Ulland TK *et al.* 2017. *Cell.* 170(4):649-663 . [PubMed](#)
6. Barrow AD *et al.* 2018. *Cell.* 172(3):534-548 . [PubMed](#)
7. Galán-Díez M, *et al.* 2022. *Cancer Discov.* . [PubMed](#)
8. Sharma GP, *et al.* 2021. *PLoS One.* 16:e0259042. [PubMed](#)
9. Deng J, *et al.* 2021. *JCI Insight.* 6:146133. [PubMed](#)
10. Aguilera T, *et al.* 2016. *Nat Commun.* 7:13898. [PubMed](#)
11. Kurelac I, *et al.* 2019. *Nat Commun.* 10:903. [PubMed](#)
12. Karlen SJ, *et al.* 2018. *J Neuroinflammation.* 15:344. [PubMed](#)
13. Saleh MM, *et al.* 2019. *Cell Host Microbe.* 25:756. [PubMed](#)
14. Kobayashi T, *et al.* 2019. *Cell.* 176:982. [PubMed](#)
15. Lee H, *et al.* 2020. *Cell Metabolism.* 31(4):822-836. [PubMed](#)
16. Karlsson J, *et al.* 2021. *Adv Funct Mater.* 31: . [PubMed](#)
17. Delacher M, *et al.* 2021. *Immunity.* 54(4):702-720.e17. [PubMed](#)
18. Zheng H, *et al.* 2021. *Frontiers in Cell and Developmental Biology.* 9:641527. [PubMed](#)
19. Song WM, *et al.* 2018. *J Exp Med.* 215:745. [PubMed](#)
20. Shmeleva EV, *et al.* 2019. *Front Immunol.* 10:1780. [PubMed](#)
21. Bratti M, *et al.* 2022. *Front Immunol.* 13:1029759. [PubMed](#)
22. Cui Z, *et al.* 2022. *Bone Res.* 10:58. [PubMed](#)
23. Nagatake T, *et al.* 2022. *Mucosal Immunol.* 15:289. [PubMed](#)
24. Webster HC, *et al.* 2020. *J Immunol Methods.* 112702:477. [PubMed](#)
25. Crncec I, *et al.* 2018. *Mol Oncol.* 12:514. [PubMed](#)
26. Kobayashi H, *et al.* 2020. *STAR Protoc.* 1:100078. [PubMed](#)
27. Schlecht A, *et al.* 2021. *Front Cell Dev Biol.* 8:618598. [PubMed](#)
28. Mathur S, *et al.* 2021. *JCI Insight.* 6: . [PubMed](#)
29. Bell BJ, *et al.* 2022. *Brain Behav Immun Health.* 23:100478. [PubMed](#)
30. Helm M, *et al.* 2022. *Life (Basel).* 12: . [PubMed](#)
31. Nishiga Y, *et al.* 2022. *Nat Cancer.* 3:1351. [PubMed](#)
32. Suter EC, *et al.* 2021. *Cell Reports.* 36(8):109587. [PubMed](#)
33. Mittal S, *et al.* 2016. *Stem Cell Reports.* 7:583-590. [PubMed](#)
34. Saika A, *et al.* 2020. *FASEB Bioadv.* 2:59. [PubMed](#)
35. Chu C, *et al.* 2016. *Dis Model Mech.* 9: 473-481. [PubMed](#)
36. Hagan AS, *et al.* 2020. *Development.* 147:00:00. [PubMed](#)
37. Kramann R, *et al.* 2018. *JCI Insight.* 3. [PubMed](#)
38. Parlet CP, *et al.* 2019. *Cell Rep.* 27:187. [PubMed](#)
39. Jiang H, *et al.* 2021. *Oncoimmunology.* 10:1943180. [PubMed](#)
40. Miller EB, *et al.* 2021. *J Neuroinflammation.* 18:235. [PubMed](#)
41. Haase C, *et al.* 2022. *Nat Methods.* 19:1622. [PubMed](#)
42. Pan YC, *et al.* 2021. *Mol Ther Oncolytics.* 20:175. [PubMed](#)
43. Li J, *et al.* 2020. *Elife.* 9:00. [PubMed](#)
44. Li Q, *et al.* 2019. *Front Cell Neurosci.* 12:520. [PubMed](#)
45. Mamedov MR, *et al.* 2018. *Immunity.* 48:350. [PubMed](#)
46. Agalave NM, *et al.* 2021. *Front Immunol.* 12:642420. [PubMed](#)
47. Katará GK, *et al.* 2020. *Mol Oncol.* 0.729861111. [PubMed](#)
48. de Lucía Finkel P, *et al.* 2021. *Sci Rep.* 11:12233. [PubMed](#)
49. Guldner IH, *et al.* 2020. *Cell.* 183(5):1234-1248.e25. [PubMed](#)
50. Engler AE, *et al.* 2020. *Cell Reports.* 33(13):108553. [PubMed](#)
51. Boeck M, *et al.* 2020. *Glia.* 1859:68. [PubMed](#)
52. Deczkowska A, *et al.* 2017. *Nat Commun.* 8:717. [PubMed](#)

53. Carbone C, *et al.* 2021. J Immunother Cancer. 9: PubMed
54. Aktories P, *et al.* 2022. Cell Rep Methods. 2:100260. PubMed
55. Dobson HE, *et al.* 2020. Mucosal Immunol. 0.901388889. PubMed
56. Bersini S, *et al.* 2020. Life Sci Alliance. 3:e201900623. PubMed
57. Durré T, *et al.* 2018. Nat Commun. 9:5178. PubMed
58. Perdigoto AL, *et al.* 2022. JCI Insight. 7: PubMed
59. Chuang CH, *et al.* 2020. Cancer Research. 81(3):567-579. PubMed
60. Ma Z, *et al.* 2022. Methods Mol Biol. 2471:49. PubMed
61. Hirata SI, *et al.* 2020. Allergy. 75:1939. PubMed
62. Goh W, *et al.* 2020. Cell Rep. 33:108285. PubMed
63. Dahlgren MW *et al.* 2019. Immunity. 50(3):707-722. PubMed
64. Nagatake T, *et al.* 2018. J Allergy Clin Immunol. 142:470. PubMed
65. Zwick M, *et al.* 2019. Front Immunol. 10:222. PubMed
66. Sakamoto K, *et al.* 2021. Immunity. 54:2321. PubMed
67. Zhang P, *et al.* 2021. J Neuroinflammation. 18:215. PubMed
68. Yi H, *et al.* 2021. Front Immunol. 12:719189. PubMed
69. Wieghofer P, *et al.* 2021. EMBO J. 40:e105123. PubMed
70. Shibuya M, *et al.* 2021. iScience. 24:103131. PubMed
71. Zhang X, *et al.* 2021. Front Pharmacol. 12:629513. PubMed
72. Ben-Yehuda H, *et al.* 2021. Mol Neurodegener. 16:39. PubMed
73. Wakabayashi T *et al.* 2018. Cell stem cell. 22(3):384-397. PubMed
74. Mao W, *et al.* 2019. J Immunother Cancer. 0.484027778. PubMed
75. Zheng X, *et al.* 2020. Int J Cancer. 146:1730. PubMed
76. Hoover AR, *et al.* 2022. Clin Transl Med. 12:e937. PubMed
77. Zhang Y, *et al.* 2021. Commun Biol. 344:4. PubMed
78. Di Pilato M, *et al.* 2021. Cell. 184(17):4512-4530.e22. PubMed
79. Glodde N *et al.* 2017. Immunity. 47(4):789-802. PubMed
80. Meng Michelle Xu *et al.* 2017. Immunity. 47(2):363-373. PubMed
81. Süß P, *et al.* 2020. Cell Reports. 30(12):4082-4095. PubMed
82. Ombrato L, *et al.* 2021. Nat Protoc. 16:872. PubMed
83. Siolas D, *et al.* 2021. Cell Reports. 36(8):109578. PubMed
84. Dubrot J, *et al.* 2021. Immunity. 54(3):571-585.e6. PubMed
85. Li X, *et al.* 2022. Oncoimmunology. 11:2118210. PubMed
86. Celorrio M, *et al.* 2022. Acta Neuropathol Commun. 10:10. PubMed
87. Nagatake T, *et al.* 2021. Int Immunol. 33:171. PubMed
88. Sakamoto K, *et al.* 2022. STAR Protoc. 3:101052. PubMed
89. Hu B, *et al.* 2020. J Clin Invest. 130:3483. PubMed
90. Dinh HQ, *et al.* 2020. Immunity. 53(2):319-334.e6. PubMed
91. Nishimura T, *et al.* 2020. Cell Stem Cell. 28(1):141-149.e3. PubMed
92. Usui-Ouchi A, *et al.* 2020. Proc Natl Acad Sci U S A. 28297:117. PubMed
93. Boddupalli CS, *et al.* 2022. Elife. 11: PubMed
94. Palma A, *et al.* 2022. Front Cell Dev Biol. 10:841548. PubMed
95. Omori S, *et al.* 2020. Cell Metabolism. 32(5):814-828.e6. PubMed
96. Zheng H, *et al.* 2021. Frontiers in Immunology. 12:645100. PubMed
97. Liu Q, *et al.* 2016. Cell Death Dis. 1.93125. PubMed
98. Scheyltjens I, *et al.* 2022. Nat Protoc. 17:2354. PubMed

RRID AB\_10899570 (BioLegend Cat. No. 103133)  
 AB\_2562559 (BioLegend Cat. No. 103134)

## Antigen Details

---

<b>Structure</b>	Protein tyrosine phosphatase (PTP) family, 180-240 kD
<b>Distribution</b>	All hematopoietic cells except mature erythrocytes and platelets
<b>Function</b>	Phosphatase, T and B cell activation
<b>Ligand/Receptor</b>	Galectin-1, CD2, CD3, CD4, TCR, CD22, Thy-1
<b>Cell Type</b>	B cells, Dendritic cells, Mesenchymal Stem Cells, Tregs
<b>Biology Area</b>	Cell Biology, Immunology, Inhibitory Molecules, Innate Immunity, Neuroscience, Neuroscience Cell Markers, Stem Cells
<b>Molecular Family</b>	CD Molecules
<b>Antigen References</b>	<ol style="list-style-type: none"> <li>1. Barclay A, <i>et al.</i> 1997. The Leukocyte Antigen FactsBook Academic Press.</li> <li>2. Trowbridge IS, <i>et al.</i> 1993. <i>Annu. Rev. Immunol.</i> 12:85.</li> <li>3. Kishihara K, <i>et al.</i> 1993. <i>Cell</i> 74:143.</li> <li>4. Pulido R, <i>et al.</i> 1988. <i>J. Immunol.</i> 140:3851.</li> </ol>
<b>Gene ID</b>	<a href="#">19264</a>


## Related Protocols

[Cell Surface Flow Cytometry Staining Protocol](#)

## Other Formats

APC anti-mouse CD45, Biotin anti-mouse CD45, FITC anti-mouse CD45, PE anti-mouse CD45, PE/Cyanine5 anti-mouse CD45, Purified anti-mouse CD45, PE/Cyanine7 anti-mouse CD45, APC/Cyanine7 anti-mouse CD45, Alexa Fluor® 488 anti-mouse CD45, Alexa Fluor® 647 anti-mouse CD45, Pacific Blue™ anti-mouse CD45, Alexa Fluor® 700 anti-mouse CD45, PerCP/Cyanine5.5 anti-mouse CD45, PerCP anti-mouse CD45, Alexa Fluor® 594 anti-mouse CD45, Brilliant Violet 421™ anti-mouse CD45, Brilliant Violet 570™ anti-mouse CD45, Brilliant Violet 510™ anti-mouse CD45, Brilliant Violet 605™ anti-mouse CD45, Purified anti-mouse CD45 (Maxpar® Ready), PE/Dazzle™ 594 anti-mouse CD45, Brilliant Violet 711™ anti-mouse CD45, Brilliant Violet 785™ anti-mouse CD45, Brilliant Violet 650™ anti-mouse CD45, APC/Fire™ 750 anti-mouse CD45, Brilliant Violet 750™ anti-mouse CD45, TotalSeq™-A0096 anti-mouse CD45, TotalSeq™-B0096 anti-mouse CD45, Ultra-LEAF™ Purified anti-mouse CD45, Spark Blue™ 550 anti-mouse CD45, Spark NIR™ 685 anti-mouse CD45, TotalSeq™-C0096 anti-mouse CD45, Spark YG™ 570 anti-mouse CD45, PE/Fire™ 640 anti-mouse CD45, APC/Fire™ 810 anti-mouse CD45, PE/Fire™ 700 anti-mouse CD45, Spark Violet™ 538 anti-mouse CD45, Spark YG™ 593 anti-mouse CD45, Spark Blue™ 574 anti-mouse CD45 Antibody

## Product Data



C57BL/6 mouse splenocytes were stained with CD45 (clone 30-F11) Brilliant Violet 421™ (filled histogram) or rat IgG2b Brilliant Violet 421™ isotype control (open histogram).

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

\*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, [www.biolegend.com/ordering#license](http://www.biolegend.com/ordering#license)). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 [www.biolegend.com](http://www.biolegend.com)  
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587